Journal Information
Vol. 47. Issue S8.
III Foro de Neumólogos en Formación
Pages 1-2 (December 2011)
Share
Share
Download PDF
More article options
Vol. 47. Issue S8.
III Foro de Neumólogos en Formación
Pages 1-2 (December 2011)
Full text access
III Foro Nacional de Neumologos en Formacion. La formacion desde la participacion
Visits
7612
Estrella Fernandez Fabrellasa, Pilar de Lucas Ramosb
a Servicio de Neumologia, Hospital Universitario Dr. Peset, Valencia, Espana, Comite de Congresos de SEPAR, Barcelona, Espana
b Servicio de Neumologia, Hospital General Universitario Gregorio Maranón, Madrid, Comité de Formación y Docencia de SEPAR, Barcelona, Espana
This item has received
Article information
Full text is only aviable in PDF
Bibliografia
[1.]
H. Pardell Alentá.
Desarrollo profesional continuo ¿de qué estamos hablando?.
Educ Med, 11 (2008), pp. 53-56
[2.]
L.K. Moores, E. Dellert, M.H. Baumann, M.J. Rosen.
Execute summary. Effectiveness of continuing medical education: American College of Chest Physicians evidence-based educational guidelines.
Chest, 135 (2009), pp. 1s-4s
[3.]
C. Jimenez Ruiz, P. De Lucas Ramos, S. Diaz Lobato, T. Garcia Carmona, C. Losada Molina, A. Martinez Verdasco, et al.
Estudio sobre la prevalencia de la EPOC en los pacientes sometidos a oxigenoterapia en la Comunidad de Madrid Estudio TOMA.
Arch Bronconeumol, 46 (2010), pp. 580-586
[4.]
D.P. Tashkin, R. Kanner, W. Bailey, S. Buist, P. Anderson, M.A. Nides, et al.
Smoking cessation in patients with chronic obstructive pulmonary disease: a double blind, placebo-controlled, randomized trial.
Lancet, 357 (2001), pp. 1571-1575
[5.]
P. Tonneses, L. Carrozzi, K.O. Fagerstron, C. Gratzioni, C. Jimenez-Ruiz, S. Nasadini, et al.
Smoking cessation in patients with respiratory disease: a high priority integral component of therapys.
Eur Respir J, 29 (2007), pp. 390-414
[6.]
D.P. Tashkin, S. Rennard, J.T. Hays, W. Ma, D. Lawrence, T.C. Lee.
Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial.
Chest, 139 (2011), pp. 591-599
[7.]
X. Munoz, M.J. Cruz, R. Orriols, F. Torres, M. Espuga, F. Morell.
Validation of specific inhalation challenge for the diagnosis of occupational asthma due to persulphate salts.
Occup Environ Med, 61 (2004), pp. 861-866
[8.]
T. Kauppinene, J. Toikkanen, D. Pedersen, R. Young, W. Ahrens, P. Boffetta, et al.
Occupational exposure to carcinogens in the European Union.
Occup Environ Med, 57 (2000), pp. 10-18
[9.]
C. Martinez Gonzalez.
Participación del neumólogo en la evaluación de la capacidad laboral de personas con enfermedades respiratorias.
Arch Bronconeumol, 44 (2008), pp. 204-212
[10.]
J. Tarrés, R. Abós-Herràndiz, C. Albertí, X. Martínez-Artés, M. Rosell-Murphy, I. García-Allas, et al.
Asbestos-related diseases in a population near a fibrous cement factory.
Arch Bronconeumol, 45 (2009), pp. 429-434
[11.]
A.R. Brody.
Asbestos lung disease..
Am J Respir Cell Mol Bio, 42 (2010), pp. 131-132
[12.]
J. Lew, A. Kapopoulou, L. Jones, S. Cole.
TubercuList-10 years after.
Tuberculosis, 91 (2011), pp. 1-7
[13.]
R. Fears, S. Kaufmann, V. Ter Meulen, A. Zumla, on behalf of the EASAC Working Group.
Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control.
Tuberculosis, 90 (2010), pp. 182-187
[14.]
A. Ginsberg.
Tuberculosis drug development: progress, challenges and the road ahead.
Tuberculosis, 90 (2010), pp. 162-167
[15.]
C.M. Bark, A. Okwera, M. Joloba, B.A. Thiel, J.G. Nakibali, S.M. Debanne, et al.
Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.
Tuberculosis, 91 (2011), pp. 257-259
[16.]
J. González-Martín, J.M. García-García, L. Anibarro, R. Vidal, J. Esteban, R. Blanquer, et al.
Documento de consenso sobre el diagnóstico, tratamiento y prevención de la tuberculosis.
Arch Bronconeumol, 46 (2010), pp. 255-274
[17.]
J. Dhillon, K. Andries, P. Phillips, D. Mitchison.
Bactericidal activity of the diarylquinoline TMC207 againts Mycobacterium tuberculosis outside and within cells.
Tuberculosis, 90 (2010), pp. 301-305
[18.]
J. Freundlich, M. Lalgondar, J. Wei, S. Swanson, E. Sorensen, E. Rubin, et al.
The Abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis.
Tuberculosis, 90 (2010), pp. 298-300
[19.]
A. Yadav, A. Singh, R. Verma, M. Mohan, A. Agrawal, A. Misra.
The devil's advocacy: When and why inhlaed therapies for tuberculosis may not work.
Tuberculosis, 90 (2011), pp. 65-66
[20.]
V. Cottin.
Interstitial lung disease: new challenges and evolving phenotypes.
Eur Respir Rev, 19 (2010), pp. 91-93
[21.]
S. Walsh, D. Hansell.
Diffuse interstitial lung disease: overlaps and uncertainties.
Eur Radiol, 20 (2010), pp. 1859-1867
[22.]
Sánchez-Varilla, S. Recio-Gllardo, J.M. Benítez-Moya, V. Almadana-Pacheco, J. Peña de Bustillo, V. Martínez-Puentes.
Variabilidad entre patólogos en el diagnóstico histológico de las enfermedades intersticiales difusas del pulmón.
Arch Bronconeumol, 41 (2005), pp. 566-568
[23.]
P. Rohatgi.
Radiological evaluation of interstitial lung disease.
Curr Opin Pulm Med, (2011), pp. 16a
[24.]
K. Shin, M. Chung, M. Jung, B. Choe, K. Lee.
Quantitative computed tomographic indexes in diffuse interstitial lung disease: correlation with physiologic tests and computed tomography visual scores.
J Comput Assist Tomogr, 35 (2011), pp. 266-271
Copyright © 2011. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?